Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Umbralisib and Ruxolitinib Phosphate in Treating Patients with Primary Myelofibrosis, Post-Polycythemia Vera MF, Post-Essential Thrombocythemia MF, Myelodysplastic / Myeloproliferative Neoplasm, or Polycythemia Vera

This phase I trial studies the side effects and best dose of umbralisib and ruxolitinib phosphate when given together in treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis (MF), post-essential thrombocythemia MF, myelodysplastic / myeloproliferative neoplasm or polycythemia vera. Umbralisib and ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Not Available
I
Savona, Michael
NCT02493530
VICCHEM1538

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

This is a Phase II, open-label, single-arm, multicenter study of intravesical BCG plus ALT-803 in patients with BCG unresponsive high grade non-muscle invasive bladder cancer (NMIBC). All patients treated in the study will receive via a urinary catheter in the bladder, BCG plus ALT-803 weekly for 6 consecutive weeks (initial induction treatment period). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. The study duration is 24 months.
Not Available
II
Chang, Sam
NCT03022825
VICCURO1784

Ibrutinib in Treating Patients with Refractory or Relapsed Lymphoma after Donor Stem Cell Transplant

Multiple Cancer Types

This phase II trial studies how well ibrutinib works in treating patients after a donor stem cell transplant for lymphoma that is not responding to treatment or has come back. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Leukemia, Lymphoma
II
Jagasia, Madan
NCT02869633
VICCBMT1651

Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations

Lung

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.
Lung
II
Horn, Leora
NCT02864992
VICCTHO1691

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX-803 / M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered twice-weekly (BIW), twice daily (BID) or once daily dose schedule in participants with advanced solid tumors. This investigation is a three part study examining M4344 alone and in combination with carboplatin, gemcitabine, and cisplatin to determine the safety and maximum tolerated dose.
Not Available
I
Not Available
NCT02278250
VICCPHI14126

Ascending Doses of AZD6738 in Combination With Chemotherapy and / or Novel Anti Cancer Agents

This is a modular, phase I / phase 1 b, open-label, multicentre study of AZD6738 administered orally in combination with cytotoxic chemotherapy regimens and / or novel anti-cancer agents, to patients with advanced malignancies. The study design allows an investigation of optimal combination dose of AZD6738 with other anti-cancer treatments, with intensive safety monitoring to ensure the safety of the patients. The initial combination to be investigated is AZD6738 with carboplatin. The second combination to be investigated is AZD6738 with Olaparib. The third combination to be investigated is AZD6738 with MEDI4736.
Not Available
I
Abramson, Vandana
NCT02264678
VICCBREP1852

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).
Not Available
I
Not Available
NCT02702492
VICCPHI1616

Anetumab Ravtansine in Treating Patients with Mesothelin Positive, Locally Advanced, or Metastatic Pancreatic Cancer That Cannot Be Removed by Surgery

Pancreatic

This phase II trial studies how well anetumab ravtansine works in treating patients with mesothelin positive pancreatic cancer that has spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as anetumab ravtansine, may find tumor cells and help kill them.
Pancreatic
II
Cardin, Dana
NCT03023722
VICCGI1720

Lenalidomide with or without Ixazomib Citrate and Dexamethasone in Treating Patients with Residual Multiple Myeloma after Donor Stem Cell Transplant

This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that remains (residual) after donor stem cell transplant. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells and may also prevent the growth of new blood vessels that are needed for cancer growth. Ixazomib citrate may stop the growth of cancer cells by interfering with proteins necessary for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether lenalidomide is more effective with or without ixazomib citrate and dexamethasone in treating residual multiple myeloma.
Not Available
II
Cornell, Robert
NCT02389517
VICCPCL1848

A Study of ZN-c5 in Subjects With Breast Cancer

This is a Phase I, open-label, multicenter, sequential dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZN-c5 administered orally in subjects with advanced estrogen receptor positive, human epidermal growth factor receptor 2 negative (ER+ / HER2-) breast cancer who have progressed following endocrine therapy. ZN-c5 will be evaluated both as monotherapy and in combination with palbociclib (IBRANCE®).
Not Available
I
Abramson, Vandana
NCT03560531
VICCBREP1899

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: